LB Pharmaceuticals Inc Increase Decrease In Operating Lease Liability
LB Pharmaceuticals Inc (LBRX) reported Increase Decrease In Operating Lease Liability of -$156.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-11
- LB Pharmaceuticals Inc increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$57.00K, a 201.79% decline year-over-year.
- LB Pharmaceuticals Inc increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$99.00K, a 5050.00% decline year-over-year.
- LB Pharmaceuticals Inc increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$98.00K, a 9900.00% decline year-over-year.
- LB Pharmaceuticals Inc increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$94.00K.
- LB Pharmaceuticals Inc increase decrease in operating lease liability for fiscal 2025 was -$134.00K.
- LB Pharmaceuticals Inc increase decrease in operating lease liability for fiscal 2024 was -$60.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$57.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$156.00K 10-Q · filed 2026-08-11 | -$254.00K derived: sum of 3 quarters · filed 2026-08-11 | -$348.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$99.00K 10-Q · filed 2026-05-12 | -$197.00K derived: sum of 2 quarters · filed 2026-05-12 | -$291.00K derived: sum of 3 quarters · filed 2026-05-12 | -$235.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$98.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$192.00K derived: sum of 2 quarters · filed 2026-03-26 | -$136.00K derived: sum of 3 quarters · filed 2026-08-11 | -$134.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | -$94.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$38.00K derived: sum of 2 quarters · filed 2026-08-11 | -$36.00K 10-Q · filed 2025-11-06 | -$35.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $56.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $58.00K 10-Q · filed 2026-08-11 | $59.00K derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-03-31 | $2.00K 10-Q · filed 2026-05-12 | $3.00K derived: sum of 2 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$60.00K 10-K · filed 2026-03-26 | ||
| 2024-09-30 | -$61.00K 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |